Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07255911 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS

Study acronym: PCOS OID
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2025 (before its estimated January 6, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions: Cabergoline 0.5 MG (Combination Product), Letrozole 2.5mg (Drug) to Cabergoline 0.5 mg (Combination Product), Letrozole 0.5mg (Drug)
    • Collaborators expanded, about 3 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Does combined Cabergoline and letrozole increase ovulation rate What medical problems do participants have when taking drug Cabergoline and Letrozole ? Researchers will compare drug combination of Cabergoline and letrozole to letrozole alone to see combined cabergoline and letrozole works better as ovulation induction. Participants will: experimental group will receive Cabergoline and Letrozole comparator group will receive letrozole alone TVS Monitoring will be done for 3 cycle for ovarian response
Trial Details
NCT Number NCT07255911
Lead Sponsor Mst.Sumyara Khatun
Collaborators: Bangladesh Medical University
Conditions
(from sponsor)		 PCOS
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov